Drug with new approach on impeding DNA repair shows promise in first clinical trial

June 15, 2020

BOSTON - In its first randomized clinical trial, a drug that targets a protein needed by cancer cells to maintain their dogged growth and division has shown considerable promise in combination with chemotherapy in patients with a common form of ovarian cancer, investigators at Dana-Farber Cancer Institute report.

As detailed in a paper published online today by The Lancet Oncology, patients with high-grade serous ovarian cancer (HGSOC) who were treated with the drug, berzosertib, and chemotherapy lived substantially longer before their disease began to worsen than did those treated with chemotherapy alone. The findings may set the stage for testing berzosertib - an inhibitor of the ATR protein - in a range of other cancers, investigators say.

"Our results in his phase 2 trial suggest that ATR inhibition in combination with chemotherapy has the potential to offer significant benefit to patients with chemotherapy-resistant HGSOC and, potentially, other tumor types where ATR plays a key role," says the study's lead author, Panagiotis Konstantinopoulos, MD, PhD, director of translational research, Gynecologic Oncology, at Dana-Farber.

Berzosertib is designed to take advantage of one of the most glaring vulnerabilities of some cancer cells. Like a tractor run non-stop, a tumor cell, driven by a constant imperative to proliferate, is apt to need frequent repairs. In a tumor cell, that involves fixing broken strands of DNA.

HGSOC, like other types of cancer, relies heavily on the ATR protein in making those repairs. That reliance becomes even greater when these cancers are treated with chemotherapy, which disrupts cells' ability to copy their DNA.

"The unbridled growth of cancer cells places enormous stress on the process of DNA replication," Konstantinopoulos explains. "ATR helps them survive that stress: its job is to coordinate the halting of the cell cycle to check if the DNA is intact or needs repair. Drugs that inhibit ATR - that deprive tumor cells of such repair - have the potential to be particularly effective in some cancers."

In the study, investigators at 11 cancer centers around the country enrolled 70 patients with HGSOC that was resistant to platinum-based chemotherapy. Half the participants were randomly assigned to receive the standard chemotherapy agent gemcitabine alone and half received gemcitabine in combination with berzosertib.

The estimated median progression-free survival of patients receiving gemcitabine alone - the period in which their disease was in retreat or stable - was 14.7 weeks. For those receiving gemcitabine and berzosertib, it was 22.9 weeks. Among patients with the most platinum resistant tumors (i.e. those who had progressed within 3 months from prior platinum-based chemotherapy), the difference was even greater: 9 weeks for gemcitabine versus 27.7 weeks for gemcitabine and berzosertib.

Side effects were similar in the two groups. Those receiving the combination therapy, however, had a higher rate of thrombocytopenia, or low blood platelet levels.
-end-
The senior authors of the paper are Geoffrey Shapiro, MD, and Ursula Matulonis, MD, of Dana-Farber. The co-authors are: Su-Chun Cheng, ScD, Susan Schumer, MD, Elizabeth Lee, MD, Anniina Farkkila, MD, Dipanjan Chowdhury, PhD, Jennifer Curtis, MS, Roxanne Quinn, Brittany Bowes, and Alan D'Andrea, MD, of Dana-Farber; Andrea Wahner Hendrickson MD, of the Mayo Clinic; Richard Penson, MD, of Massachusetts General Hospital; Austin Doyle, MD, and Elise Kohn, MD, of the National Cancer Institute; Linda Duska, MD, of the University of Virginia Cancer Center; Marta Crispens, MD, of Vanderbilt University; Alexander Olawaiye, MD, of University of Pittsburgh Cancer Institute; Ira Winer, MD, of Wayne State University; Lisa Barrolhet, MD, of University of Wisconsin Hospital and Clinics; Siqing Fu, MD, MD Anderson Cancer Center; Michael McHale, MD, of University of California San Diego Moores Cancer Center; and Russell Schilder, MD, of Thomas Jefferson University, Sidney Kimmel Cancer Center.

The study was funded by the National Cancer Institute-Cancer Therapy Evaluation Program. It was supported by NIH grant UM1 CA186709 to Dr. Geoff Shapiro.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is one of the only hospitals ranked in the top five by U.S. News and World Report in both adult and pediatric cancer care. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

Dana-Farber Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.